Please assess the completion status of the following clinical trial:

Trial Title: Endometrial Rejuvenation Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients planning to undergo a frozen-thawed embryo transfer cycle using a single euploid blastocyst.~2. Patients who have previously undergone at least 2 unsuccessful frozen-thawed embryo transfer cycles, defined as failure to achieve a clinical pregnancy (visualization of intrauterine gestational sac on ultrasound) or a cancelled embryo transfer cycle due to inadequate endometrial thickness.~3. Patients with a diagnosis of thin endometrial lining (less than 6 mm maximum thickness) during at least one prior unsuccessful embryo transfer cycle.~4. Initiation of the most recent unsuccessful frozen-thawed embryo transfer cycle with a thin endometrial lining must have occurred after January 1, 2017.~Exclusion Criteria:~1. Fewer than 2 prior unsuccessful frozen-thawed embryo transfer cycles.~2. Most recent unsuccessful frozen-thawed embryo transfer prior to January 1, 2017.~3. No euploid embryos available for transfer.~4. Mullerian anomalies, excluding arcuate uterus~5. Submucosal fibroids~6. History of uterine surgery, excluding polypectomy, D\&C, and Cesarean section~7. Communicating hydrosalpinx without plans for surgical correction prior to study enrollment.~8. Failure of patient to agree to enrollment in study with written consent.~9. History of drug sensitivity or adverse reaction to AMD3100 (plerixafor).~10. Pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Patients in this arm will not receive the study drug. A placebo of normal saline will be injected subcutaneously and the D\&C procedure will be completed.
- Intervention (Type: EXPERIMENTAL): Patients in this arm will receive a dose of the study drug, AMD3100, injected subcutaneously and the D\&C procedure will be completed.

Based on this trial design, predict the completion outcome and termination type (if applicable).